Updates are available Correction dated 2021-03-13
Click to view Correction: https://doi.org/10.1038/s41375-021-01197-2
-
Authors
Hershberger, Courtney E. http://orcid.org/0000-0002-2195-989X
Moyer, Devlin C.
Adema, Vera
Kerr, Cassandra M.
Walter, Wencke
Hutter, Stephan
Meggendorfer, Manja
Baer, Constance
Kern, Wolfgang
Nadarajah, Niroshan
Twardziok, Sven
Sekeres, Mikkael A.
Haferlach, Claudia
Haferlach, Torsten
Maciejewski, Jaroslaw P.
Padgett, Richard A. http://orcid.org/0000-0002-2910-1134
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL132071, R01HL123904)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
- License Information
-
More Information
Article History
Received: 2 April 2020
Revised: 8 July 2020
Accepted: 22 July 2020
First Online: 4 August 2020
Change Date: 13 March 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01197-2
Compliance with ethical standards
:
: TH, CH, and WK serve as the management board of the MLL Munich Leukemia Laboratory. NN, ST, SH, MM, WW, and CB are employed by the MLL Munich Leukemia Laboratory. The MLL offers diagnostic services for leukemias and lymphomas, including cytomorphology, cytochemistry, immunophenotyping, cytogenetics, FISH, and a broad spectrum of molecular assays. In addition, MLL runs several research studies based on a combination of methods for routine use and also including whole genome sequencing and whole transcriptome sequencing.
